Results: 9

PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice

Arq. bras. cardiol; 112 (4), 2019
Abstract Coronary artery disease (CAD) is one of the leading causes of mortality. High circulating levels of low-density lipoprotein (LDL) in the blood are associated with cardiovascular mortality, whether through an etiological role or through its association with the progression of CAD per se. Randomiz...

Lipid profile and statin use in critical care setting: implications for kidney outcome

Einstein (Säo Paulo); 17 (3), 2019
ABSTRACT Objective: To determine whether pre-hospital statin use is associated with lower renal replacement therapy requirement and/or death during intensive care unit stay. Methods: Prospective cohort analysis. We analyzed 670 patients consecutively admitted to the intensive care unit of an academic t...

Omega-3 fatty acids, inflammatory status and biochemical markers of patients with systemic lupus erythematosus: a pilot study

Rev. bras. reumatol; 57 (6), 2017
Abstract Background: Studies have shown that omega-3 fatty acids reduce the concentrations of eicosanoids, cytokines, chemokines, C-reactive protein (CRP) and other inflammatory mediators. Objective: To investigate the effects of omega-3 fatty acids on circulating levels of inflammatory mediators and b...

Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases

Arq. bras. cardiol; 109 (5), 2017
Abstract Phytosterols are bioactive compounds found in foods of plant origin, which can be divided into plant sterols and plant stanols. Clinical studies consistently indicate that the intake of phytosterols (2 g/day) is associated with a significant reduction (8-10%) in levels of low-density lipoprotein...

Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe

Arq. bras. cardiol; 106 (4), 2016
Abstract Background: The effect of statins on the endothelial function in humans remains under discussion. Particularly, it is still unclear if the improvement in endothelial function is due to a reduction in LDL-cholesterol or to an arterial pleiotropic effect. Objective: To test the hypothesis that ...

Efecto de atorvastatina en pacientes con hipercolesterolemia primaria
Effect of atorvastatin in patients with primary hypercholesterolemia

Rev. chil. cardiol; 18 (1), 1999
Objetivo. Conocer el descenso que produce atorvastatina, un nuevo inhibidor de la 3-hidroxi metiglutaril coenzima A reductasa ( HMG- CoA ), en los niveles del colesterol de la lipoprotéina de baja densidad c- LDL demás parámetros lipídicos a los 30 días y, observar , si esta reducción del c-LDL se ...

Efeitos da pravastatina nas lipoproteínas, Lp(a), apo B e apo A-I em pacientes com hipercolesterolemia primária

Arq. bras. cardiol; 62 (6), 1994
PURPOSE--To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerability in primary hypercholesterolemic patients in our outpatient lipid clinic. METHODS--Twenty-two primary hypercholesterolemic patients were evaluated. They had all been treated previously with othe...

As açöes dos inibidores da HMG CoA redutase säo influenciadas por variaçöes do peso corpóreo? Estudo com a pravastatina
The actions of reductase HMG CoA inhibitors were influenced with body weight variations? Study with pravastatin

Arq. bras. med; 68 (1), 1994
Dispondo dos resultados do estudo multicêntrico que avaliou a eficácia da pravastatina em pacientes com hipercolesterolemia primária, os AA investigaram se a intensidade das respostas guardava ligaçäo com a variaçäo do peso corpóreo, ocorrida em 12 semanas de observaçäo. Foi analisado o comport...

Ciprofibrato: nueva terapia farmacológica en la hipertrigliceridemia
Ciprofibrate: a new pharmacologic agent for treatment of hypertriglyceridemia

Rev. chil. cardiol; 12 (2), 1993
En 16 hombres portadores de dislipidemia IIb, excluyendodiabéticos y otras patologías graves, evaluamos prospectivamente el efecto en colesterol total, colesterol LDL, colesterol HDL y triglicéridos del ciprofibrato. Después de cuatro semanas con régimen adecuado y sin hipolipemiantes, se les indica...